TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25122648

Group type: EXPERIMENTAL
Intervention: 1.8 g/d of EPA+DHA from fish oil (FO)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: 1.3 g/d of EPA+DHA from fish oil (FO)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: 0.9 g/d of EPA+DHA from fish oil (FO)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Plant sterols (PSs) with varying amounts of FO
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control spread (no PSs, no FO)
Number of subjects: 332
Study: 22209059

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 55
Study: 21531577

Group type: EXPERIMENTAL
Intervention: Subcutaneous treprostinil treatment
Number of subjects: 811
Study: 18082107

Group type: EXPERIMENTAL
Intervention: Medicated patients with schizophrenia
Number of subjects: 28

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 28
Study: 15542572

Group type: EXPERIMENTAL
Intervention: Static handgrip exercise at 30% of maximal voluntary contraction for 3 minutes
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Posthandgrip ischemia for 3 minutes
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Mental arithmetic task for 3 minutes
Number of subjects: 9
Study: 12062463

Group type: EXPERIMENTAL
Intervention: Minimal methadone treatment with daily INH DOPT (n=35)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Standard methadone treatment with daily INH DOPT (n=37)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Routine care referral to TB clinic for monthly INH supplies without DOPT and without methadone treatment (n=39)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Completion of preventive therapy
Number of subjects: 111
Study: 11280842

Group type: EXPERIMENTAL
Intervention: Diabetes education
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 39
Study: 8533541

Group type: EXPERIMENTAL
Intervention: Mivacurium chloride 0.11 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mivacurium chloride 0.15 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mivacurium chloride 0.19 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mivacurium chloride (all doses)
Number of subjects: 20
Study: 2170852

Group type: EXPERIMENTAL
Intervention: 50 mg BC-PS
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 75 mg BC-PS
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 626722

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 30681791

Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% lotion
Number of subjects: 766

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 766
Study: 30257292

Group type: EXPERIMENTAL
Intervention: O-Arm
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: AIRO
Number of subjects: 22
Study: 27192505

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) membrane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paper patch technique
Number of subjects: 60
Study: 24568751

Group type: EXPERIMENTAL
Intervention: 2 positive activities
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: 4 positive activities
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: 6 positive activities
Number of subjects: 417

Group type: COMPARATOR
Intervention: 0 positive activities (control group)
Number of subjects: 417
Study: 22393084

Group type: EXPERIMENTAL
Intervention: Pertuzumab monotherapy (840 mg loading dose, then 420 mg every 3 weeks)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combination of pertuzumab and trastuzumab (pertuzumab at the same dose, trastuzumab 4 mg/kg loading dose and then 2 mg/kg weekly or 8 mg/kg loading dose and then 6 mg/kg every 3 weeks)
Number of subjects: 29
Study: 20642918

Group type: EXPERIMENTAL
Intervention: Walking epidural analgesia with 15 ml of 0.1% Bupivacaine + 0.5 mg/ml Tramadol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Injection Nalbuphine 10 mg intramuscular (control group A)
Number of subjects: 100
Study: 17936185

Group type: EXPERIMENTAL
Intervention: Vitamin E 3200 IU/day for 20 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin E doses of 1600 IU and 3200 IU/day for 16 weeks
Number of subjects: 0
Study: 15009332

Group type: EXPERIMENTAL
Intervention: Self-selected music during waiting period
Number of subjects: 113

Group type: COMPARATOR
Intervention: Usual relaxing activities in waiting room
Number of subjects: 113
Study: 11306897

Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg OD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alfuzosin 2.5 mg t.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9853647

Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 32
Study: 7857844

Group type: COMPARATOR
Intervention: Single freeze-thaw cycle
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Double freeze-thaw cycle
Number of subjects: 300

Group type: COMPARATOR
Intervention: Single freeze-thaw cycle for plantar warts
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Double freeze-thaw cycle for plantar warts
Number of subjects: 300
Study: 2504140

Group type: EXPERIMENTAL
Intervention: Overnight nasogastric nutritional supplementation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no nasogastric feeding)
Number of subjects: 11
Study: 1099449

Group type: EXPERIMENTAL
Intervention: Oral delta‐9‐tetrahydrocannabinol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30784012

Group type: EXPERIMENTAL
Intervention: Ergocalciferol 100,000 IU per week
Number of subjects: 94

Group type: COMPARATOR
Intervention: Ergocalciferol 40,000 IU per week
Number of subjects: 94
Study: 30311701

Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg/grazoprevir 100 mg once daily for 12 weeks
Number of subjects: 489

Group type: COMPARATOR
Intervention: Placebo (deferred treatment)
Number of subjects: 489
Study: 28598760

Group type: EXPERIMENTAL
Intervention: Polyurethane (PU group, Mepilex)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Polyurethane with silicone membrane (PUSM group, Mepilex border)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Transparent, breathable film (TBF group, Mepitel film)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Cotton gauze dressings (CG group)
Number of subjects: 98
Study: 25649881

Group type: EXPERIMENTAL
Intervention: Clarithromycin (CAM) + carbocysteine (S-CMC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: S-CMC
Number of subjects: 0
Study: 24746035

Group type: EXPERIMENTAL
Intervention: Neurofeedback training (NFT), 8 sessions
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study: 22112605

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lifestyle Modification (LSM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No LSM (Control)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 50
Study: 20192128

Group type: EXPERIMENTAL
Intervention: Holding hands widened
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arm positions larger than shoulder width
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Holding a large object or wearing a large object
Number of subjects: 0
Study: 17389554

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg oral dose
Number of subjects: 57
Study: 16107035

Group type: EXPERIMENTAL
Intervention: Bu Yang Huan Wu Soup (BYHWS)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tong Mai Soup (TMS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no medication affecting coagulation)
Number of subjects: 48
Study: 11826641

Group type: EXPERIMENTAL
Intervention: 1% sodium hyaluronate (HA) 6 mg, injected in the upper compartments of the involved TMJs, three to four injections as one course.
Number of subjects: 67

Group type: COMPARATOR
Intervention: Prednisolone (PS) 12.5 mg, injected once a week, three to four injections as one course.
Number of subjects: 67
Study: 10599905

Group type: EXPERIMENTAL
Intervention: Systemic doxycycline at a dosage of 100 mg/day for 14 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no doxycycline administration)
Number of subjects: 20
Study: 8943436

Group type: EXPERIMENTAL
Intervention: Digitally compressed echocardiographic images (JPEG algorithm at 20:1 compression)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Uncompressed digital images
Number of subjects: 179

Group type: COMPARATOR
Intervention: S-VHS images (control)
Number of subjects: 179
Study: 1928815

Group type: EXPERIMENTAL
Intervention: Pentoxifylline for six months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for six months
Number of subjects: 40
Study: 6357929

Group type: EXPERIMENTAL
Intervention: Propafenone (600 mg daily)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Aprindine (150 mg daily for the first two days and 50 mg every 12 hours subsequently)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31008867

Group type: EXPERIMENTAL
Intervention: TEG-guided blood product transfusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional transfusion
Number of subjects: 60
Study: 28889781

Group type: EXPERIMENTAL
Intervention: Intrauterine cleaning
Number of subjects: 206

Group type: COMPARATOR
Intervention: Omission of cleaning
Number of subjects: 206
Study: 28463040

Group type: COMPARATOR
Intervention: UD‐DPI (400 μg, 0.8% lactose blend)
Number of subjects: 0

Group type: COMPARATOR
Intervention: UD‐DPI (0.8% lactose blend)
Number of subjects: 0
Study: 25586959

Group type: EXPERIMENTAL
Intervention: fMRI and EEG data acquisition during contextual cueing task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EEG data recorded in isolation one week later
Number of subjects: 0
Study: 23727501

Group type: EXPERIMENTAL
Intervention: Instructor-led intervention (ILI)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Self-help (SH)
Number of subjects: 71
Study: 21849595

Group type: EXPERIMENTAL
Intervention: Mixed meal (dried meat, butter, and white bread)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lipid component (butter alone)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Protein component (dried meat alone)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no meal)
Number of subjects: 8
Study: 19721147

Group type: EXPERIMENTAL
Intervention: Fixed-bearing prosthesis
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mobile-bearing prosthesis
Number of subjects: 120
Study: 17251482

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (300 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Alprostadil (60 mug)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 14698543

Group type: EXPERIMENTAL
Intervention: Vinorelbine (V) 25mg/m2 IV infusion + Gemcitabine (G) 1000 mg/m2 IV infusion on days 1 and 8 of each 21-day cycle
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vinorelbine (V) and Gemcitabine (G)
Number of subjects: 50
Study: 12790969

Group type: EXPERIMENTAL
Intervention: 0.1% GTN
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.2% GTN
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.4% GTN
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 9562938

Group type: EXPERIMENTAL
Intervention: Captopril (25-75 mg/day)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Fosinopril (10-20 mg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Historical sample (no ACE-inhibitor therapy)
Number of subjects: 52
Study: 7698127

Group type: EXPERIMENTAL
Intervention: Ceruloplasmin
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: High low density lipoprotein cholesterol
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Low high density lipoprotein cholesterol
Number of subjects: 140

Group type: COMPARATOR
Intervention: Ferritin
Number of subjects: 140
Study: 3052769

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 221

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 221
Study: 30870225

Group type: EXPERIMENTAL
Intervention: Adjuvant capecitabine monotherapy for 8 cycles
Number of subjects: 233

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 233
Study: 28438924

Group type: EXPERIMENTAL
Intervention: Gatifloxacin, rifampin, and isoniazid for 4 months (pyrazinamide for the first 2 months)
Number of subjects: 1686

Group type: COMPARATOR
Intervention: Standard treatment (rifampin and isoniazid for 6 months; pyrazinamide and ethambutol for 2 months)
Number of subjects: 1686
Study: 25088963

Group type: EXPERIMENTAL
Intervention: Denosumab 60mg subcutaneous injections twice yearly
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 22465206

Group type: EXPERIMENTAL
Intervention: Emotional support
Number of subjects: 94

Group type: COMPARATOR
Intervention: Global support scores
Number of subjects: 94
Study: 22013794

Group type: EXPERIMENTAL
Intervention: Lipid-reducing red rice minute powder (LRRMP) 175 mg/pill, 2 pills daily for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Xuezhikang Capsule 300 mg/pill, 2 pills daily for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lovastatin Tablet 20 mg/tablet, 1 tablet daily for 6 months
Number of subjects: 60
Study: 19079839

Group type: EXPERIMENTAL
Intervention: High-soya diet (two daily servings with 3035mg isoflavones per serving)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-soya diet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High soya intake early in life
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Soya intake during adulthood
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MIP‐1b, adiponectin, IL‐6 and CRP
Number of subjects: 24
Study: 16697324

Group type: EXPERIMENTAL
Intervention: Sitaxsentan 100 mg
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Sitaxsentan 50 mg
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Bosentan (open-label)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study: 16091234

Group type: EXPERIMENTAL
Intervention: Various pharmacologic interventions for painful HIV neuropathy, including experimental agents studied in recent and ongoing clinical trials.
Number of subjects: 0
Study: 11306776

Group type: EXPERIMENTAL
Intervention: Arginine esterase 0.005 unit/kg x 2 times/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Heparin (activated partial thromboplastin time 2‐3 times of baseline value)
Number of subjects: 50
Study: 9325477

Group type: EXPERIMENTAL
Intervention: Buspirone (BSR) 30 mg daily for 12 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Amitriptyline (AML) 50 mg daily for 12 weeks
Number of subjects: 58
Study: 7524296

Group type: EXPERIMENTAL
Intervention: Amiodarone 100 mg/day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 2573325

Group type: EXPERIMENTAL
Intervention: Cicletanine 50 mg/d
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cicletanine 100 mg/d
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 239414

Group type: EXPERIMENTAL
Intervention: Terbutaline (5 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Ephedrine (25 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30566611

Group type: EXPERIMENTAL
Intervention: Core model (age, hypertension, World Federation of Neurosurgical Societies grade)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Neuroimaging model (aneurysm size/location, Fisher score)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Full model (Core + neuroimaging + treatment type)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Overall models
Number of subjects: 338
Study: 30540224

Group type: EXPERIMENTAL
Intervention: Ethnic-concordance condition (Turkish minority physician)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Ethnic-discordance condition (German majority physician)
Number of subjects: 256
Study: 27911344

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 280
Study: 25361548

Group type: EXPERIMENTAL
Intervention: Helical Tomotherapy (TOMO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Step-and-shoot IMRT (SSIMRT)
Number of subjects: 20
Study: 24295464

Group type: EXPERIMENTAL
Intervention: Individually supported self‐monitoring using adapted DBT diary cards (DC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group‐based DBT
Number of subjects: 0
Study: 21261966

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team consultation lasting up to one hour with up to four case-specific health care professionals.
Number of subjects: 94

Group type: COMPARATOR
Intervention: Normal primary care services (Control).
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team consultation.
Number of subjects: 94
Study: 19906002

Group type: EXPERIMENTAL
Intervention: estradiol valerate 2 mg + testosterone undecanoate 40 mg (E/T)
Number of subjects: 50

Group type: COMPARATOR
Intervention: estradiol valerate 2 mg + placebo (E/P)
Number of subjects: 50
Study: 16764134

Group type: EXPERIMENTAL
Intervention: Aqua Meron
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Vitremer
Number of subjects: 86
Study: 15635515

Group type: EXPERIMENTAL
Intervention: Ropivacaine 5 mg/mL
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Bupivacaine 5 mg/mL
Number of subjects: 32
Study: 10905386

Group type: EXPERIMENTAL
Intervention: Endurance training intervention lasting 5 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 8880037

Group type: EXPERIMENTAL
Intervention: Ample choice of food items consisting of mainly one macronutrient each offered 4 and 6 times per day with varying macronutrient compositions
Number of subjects: 68
Study: 1557008

Group type: EXPERIMENTAL
Intervention: Endarterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical care alone
Number of subjects: 0
Study: 6396247

Group type: EXPERIMENTAL
Intervention: Tioconazole
Number of subjects: 69

Group type: COMPARATOR
Intervention: Miconazole
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both tioconazole and miconazole
Number of subjects: 69
Study: 30760332

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) with silver-impregnated dressings via RENASYS TOUCH vacuum pump
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard therapy consisting of Acticoat TM and Mepitel TM
Number of subjects: 104
Study: 28978680

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNSs) provided to women during pregnancy and the first 6 months postpartum and/or to their children from 6 to 18-24 months
Number of subjects: 4669

Group type: COMPARATOR
Intervention: Non-Lipid-based nutrient supplements (non-LNS)
Number of subjects: 4669
Study: 26926660

Group type: EXPERIMENTAL
Intervention: externally-supported intervention
Number of subjects: 1767

Group type: EXPERIMENTAL
Intervention: teacher-supported intervention
Number of subjects: 1767

Group type: COMPARATOR
Intervention: wait-list control
Number of subjects: 1767
Study: 24445391

Group type: EXPERIMENTAL
Intervention: Plasma renin concentration (PRC)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Plasma renin activity (PRA)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Primary aldosteronism patients
Number of subjects: 88
Study: 22246216

Group type: EXPERIMENTAL
Intervention: Clinical Pilates (n = 44)
Number of subjects: 87

Group type: COMPARATOR
Intervention: General exercise (n = 43)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Clinical Pilates
Number of subjects: 87

Group type: COMPARATOR
Intervention: General exercise
Number of subjects: 87
Study: 21057560

Group type: EXPERIMENTAL
Intervention: RHAMM expression tested by RT-PCR in chronic phase CML patients (44 patients)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RHAMM expression tested by RT-PCR in accelerated/blastic phase CML patients (16 patients)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RHAMM positive patients in chronic phase CML
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 60
Study: 17504895

Group type: EXPERIMENTAL
Intervention: GH dose of 1 mg/m(2).d (group A)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: GH dose of 2 mg/m(2).d (group B)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: GH therapy
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Baseline free IGF‐I and IGFBP‐3
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Baseline bone age delay, target height SDS, baseline height SDS, and GH dose
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Baseline free IGF‐I
Number of subjects: 73
Study: 15354005

Group type: EXPERIMENTAL
Intervention: Scopolamine 0.4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Promethazine 25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meclizine 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg
Number of subjects: 0
Study: 11676153

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 0
Study: 9678531

Group type: EXPERIMENTAL
Intervention: Evening s.c. GH injections (2 IU)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Morning s.c. GH injections (2 IU)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: No GH administration
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Two boluses i.v. GH (at 2000 and 0200 h)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Eight boluses i.v. GH (at 3 h intervals starting at 2000 h)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Continuous i.v. infusion of GH (2000-2000 h)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy untreated subjects (control group)
Number of subjects: 14
Study: 7734465

Group type: EXPERIMENTAL
Intervention: High intensity neurobehavioral therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Lower intensity control therapy
Number of subjects: 62